Deltex Medical has established itself as a top contender in the global haemodynamic monitoring technology industry. Its oesophageal Doppler monitoring (ODM) platform stands out for its ability to provide real-time and accurate information to anaesthetists, enabling them to administer fluids and drugs in surgical patients with greater precision. The company has an impressive track record, backed by solid clinical data, demonstrating that the ODM system helps clinicians achieve better surgical outcomes, reduce complications, and shorten patient hospital stays. Deltex Medical's latest study, FEDORA, showed significant reductions in overall complication risks and acute kidney injury, underscoring the potential of the company's innovative technology to revolutionize surgical and medical care.